Catalyst Prescription drugs, Inc. (NASDAQ:CPRX – Get Score) hit a brand new 52-week excessive throughout mid-day buying and selling on Wednesday after Truist Monetary raised their value goal on the inventory from $17.00 to $18.00. Truist Monetary at the moment has a purchase ranking on the inventory. Catalyst Prescription drugs traded as excessive as $19.06 and final traded at $18.98, with a quantity of 5024 shares altering palms. The inventory had beforehand closed at $18.60.
A variety of different analysts have additionally weighed in on CPRX. HC Wainwright elevated their value goal on shares of Catalyst Prescription drugs from $18.00 to $24.00 and gave the inventory a “purchase” ranking in a analysis report on Wednesday. Roth Capital lowered shares of Catalyst Prescription drugs from a “purchase” ranking to a “impartial” ranking and elevated their value goal for the inventory from $10.00 to $15.50 in a analysis report on Wednesday, August twenty fourth. Piper Sandler elevated their value goal on shares of Catalyst Prescription drugs from $18.00 to $20.00 and gave the inventory an “chubby” ranking in a analysis report on Tuesday. Lastly, StockNews.com lowered shares of Catalyst Prescription drugs from a “strong-buy” ranking to a “purchase” ranking in a analysis report on Wednesday, November ninth. One analysis analyst has rated the inventory with a maintain ranking and 4 have issued a purchase ranking to the corporate’s inventory. In accordance with information from MarketBeat.com, the corporate has a consensus ranking of “Average Purchase” and a consensus value goal of $19.38.
Insider Exercise
In different information, insider Preethi Sundaram offered 56,786 shares of the inventory in a transaction that occurred on Friday, November eleventh. The shares had been offered at a mean value of $16.38, for a complete transaction of $930,154.68. The transaction was disclosed in a submitting with the SEC, which could be accessed by this hyperlink. In associated information, insider Preethi Sundaram offered 56,786 shares of the inventory in a transaction that occurred on Friday, November eleventh. The shares had been offered at a mean value of $16.38, for a complete transaction of $930,154.68. The transaction was disclosed in a authorized submitting with the Securities & Alternate Fee, which is accessible by this hyperlink. Additionally, COO Steve Miller offered 80,000 shares of the inventory in a transaction that occurred on Monday, November twenty first. The shares had been offered at a mean value of $15.28, for a complete transaction of $1,222,400.00. Following the sale, the chief working officer now straight owns 573,791 shares of the corporate’s inventory, valued at roughly $8,767,526.48. The disclosure for this sale could be discovered right here. During the last ninety days, insiders have offered 1,002,703 shares of firm inventory value $15,581,756. Company insiders personal 14.10% of the corporate’s inventory.
Institutional Traders Weigh In On Catalyst Prescription drugs
A variety of hedge funds and different institutional buyers have just lately purchased and offered shares of CPRX. Trainer Retirement System of Texas raised its holdings in shares of Catalyst Prescription drugs by 8.3% within the first quarter. Trainer Retirement System of Texas now owns 20,193 shares of the biopharmaceutical firm’s inventory value $167,000 after shopping for a further 1,551 shares over the past quarter. Swiss Nationwide Financial institution raised its holdings in shares of Catalyst Prescription drugs by 6.6% within the first quarter. Swiss Nationwide Financial institution now owns 231,700 shares of the biopharmaceutical firm’s inventory value $1,921,000 after shopping for a further 14,300 shares over the past quarter. GSA Capital Companions LLP raised its holdings in shares of Catalyst Prescription drugs by 51.5% within the first quarter. GSA Capital Companions LLP now owns 36,241 shares of the biopharmaceutical firm’s inventory value $300,000 after shopping for a further 12,313 shares over the past quarter. Financial institution of New York Mellon Corp raised its holdings in shares of Catalyst Prescription drugs by 16.7% within the first quarter. Financial institution of New York Mellon Corp now owns 569,542 shares of the biopharmaceutical firm’s inventory value $4,722,000 after shopping for a further 81,325 shares over the past quarter. Lastly, American Century Corporations Inc. raised its holdings in shares of Catalyst Prescription drugs by 56.7% within the first quarter. American Century Corporations Inc. now owns 345,348 shares of the biopharmaceutical firm’s inventory value $2,863,000 after shopping for a further 124,924 shares over the past quarter. Hedge funds and different institutional buyers personal 74.16% of the corporate’s inventory.
Catalyst Prescription drugs Worth Efficiency
The inventory’s fifty day easy shifting common is $15.35 and its 200-day easy shifting common is $12.41. The agency has a market cap of $1.97 billion, a PE ratio of 30.49 and a beta of 1.25.
Catalyst Prescription drugs (NASDAQ:CPRX – Get Score) final issued its earnings outcomes on Wednesday, November ninth. The biopharmaceutical firm reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Catalyst Prescription drugs had a internet margin of 34.90% and a return on fairness of 28.53%. The agency had income of $57.24 million through the quarter, in comparison with analysts’ expectations of $53.80 million. Analysts count on that Catalyst Prescription drugs, Inc. will put up 0.73 earnings per share for the present 12 months.
Catalyst Prescription drugs Firm Profile
(Get Score)
Catalyst Prescription drugs, Inc, a commercial-stage biopharmaceutical firm, focuses on creating and commercializing therapies for folks with uncommon debilitating, continual neuromuscular, and neurological illnesses in america. It provides Firdapse, an amifampridine phosphate tablets for the remedy of sufferers with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the remedy of pediatric LEMS sufferers.
Featured Tales
This instantaneous information alert was generated by narrative science expertise and monetary information from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial crew previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Catalyst Prescription drugs, you may wish to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Catalyst Prescription drugs wasn’t on the record.
Whereas Catalyst Prescription drugs at the moment has a “Average Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
